Seeking subjects with Gout who have not met target Uric Acid levels on Xanthine Oxidase Inhibitor Alone.

Enroll Now

Type of Study:

Gout

Title of Study:

A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone

Short Title:

Seeking subjects with Gout who have not met target Uric Acid levels on Xanthine Oxidase Inhibitor Alone.

Study Length: Up to 5 years

Target Age/Sex: 18-65, Male and Female

Benefits:

Participants will receive at no cost: Study medication, Study related lab work and medical exams. Subject will also receive a stipend for time/travel related to the study.

Link: ClinicalTrials.gov